Omni Bridgeway has agreed to fund a class action against Mesoblast Limited (ASX:MSB) on behalf of shareholders who acquired Mesoblast shares on the ASX and “over the counter” American Depositary Receipts (ADRs) between 22 February 2018 and 17 December 2020 (Claim Period).
Mesoblast shareholders who acquired shares and ADRs during the Claim Period may be entitled to compensation for losses arising out of Mesoblast’s alleged breaches of its continuous disclosure obligations and/or by Mesoblast engaging in misleading and deceptive conduct.
The class action will be run by law firm Phi Finney McDonald.
